Sea-snail venom may lead to fast-acting diabetes medication

Venom from a species of marine cone snails may help develop 'ultra-fast-acting' insulin, leading to more efficient therapies for diabetes patients, a new study has found. Researchers have successfully determined the 3D structure of a cone snail venom insulin, showing how these highly efficient natural proteins called Con-Ins G1 can operate faster than human insulin.

The team also discovered that Con-Ins G1 was able to bind to human insulin receptors, signifying the potential for its translation into a human therapeutic. Researchers led by Mike Lawrence from Walter and Eliza Hall Institute of Medical Research in Australia, utilised the Australian Synchrotron to create and analyse the 3D structure of the cone snail venom insulin protein with exciting results. "We found that cone snail venom insulins work faster than human insulins by avoiding the structural changes that human insulins undergo in order to function - they are essentially primed and ready to bind to their receptors," Lawrence said.

Human insulins could be considered 'clunky' by comparison, he said. "The structure of human insulins contain an extra 'hinge' component that has to open before any 'molecular handshake' or connection between insulin and receptor can take place," Lawrence added. "By studying the three-dimensional structure of this snail venom insulin we've found how to dispense with this 'hinge' entirely, which may accelerate the cell signalling process and thus the speed with which the insulin takes effect," he said.

The team's findings build on earlier studies from 2015, when the University of Utah reported that the marine cone snail Conus geographus used an insulin-based venom to trap its prey. Unsuspecting fish prey would swim into the invisible trap and immediately become immobilised in a state of hyperglycaemic shock induced by the venom.

Researchers said it was fascinating to uncover how the cone snail insulin was able to have such a rapid effect on its prey and that the peptide had therapeutic potential in humans. "We were thrilled to find that the principles of cone snail venom insulins could be applied to a human setting," said Helena Safavi-Hemami from the University of Utah. "Our colleagues have shown that the cone snail insulin can 'switch on' human insulin cell signalling pathways, meaning the cone snail insulin is able to successfully bind to human receptors," she said.

"The next step in our research, which is already underway, is to apply these findings to the design of new and better treatments for diabetes, giving patients access to faster-acting insulins," she added. The study appears in the journal Nature Structural and Molecular Biology.